Impact of stereotactic body radiotherapy vs palliative radiotherapy on oncologic outcomes of patients with metastatic kidney cancer concomitantly treated with immune checkpoint inhibitors: a preliminary, multicentre experience.

Authors :: Francolini G
Campi R
Di Cataldo V
Detti B
Loi M
Triggiani L
La Mattina S
Borghetti P
Magrini SM
Nicosia L
Alongi F
Ghirardelli P
Vavassori V
Allegra AG
Aquilano M
Scoccimarro E
Peruzzi A
Pastina P
Visani L
Desideri I
Serni S
Meattini I
Livi L
Source :: Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico [Clin Transl Oncol] 2022 Oct; Vol. 24 (10), pp. 2039-2043. Date of Electronic Publication: 2022 Jun 23.
Publication Year :: 2022
Abstract: Purpose: To explore the benefit yielded by radiotherapy (RT), we report a series of metastatic renal cell carcinoma (RCC) patients treated with concomitant RT plus Nivolumab.<br />Methods/patients: Patients undergoing Nivolumab treatment plus concomitant RT (ablative or palliative) were included. RT was defined Ablative if >5 Gy/fraction were delivered.<br />Results: Ablative RT intent was the only independent predictor of both progression free and overall survival (HR 3.51, 95% CI 1.6-7.5, p = 0.0012 and HR 2.8, 95% CI 0.99-8.07, p = 0.05, respectively).<br />Conclusion: Ablative RT may improve oncologic outcomes in selected patients with metastatic RCC treated with Nivolumab as compared to palliative RT.<br /> (© 2022. The Author(s).)

Subjects :: Humans
Immune Checkpoint Inhibitors
Nivolumab
Carcinoma, Renal Cell
Kidney Neoplasms
Radiosurgery

Language :: English
ISSN :: 1699-3055
Volume :: 24
Issue :: 10
Database :: MEDLINE
Journal :: Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
Publication Type :: Academic Journal
Accession number :: 35739349
Full Text :: https://doi.org/10.1007/s12094-022-02844-5

Full Text Access

Tools